Alpha-1 Acid Glycoprotein Assay for Stem Cell Heart Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an in vitro assay to determine the binding capacity of stem cells to mammalian heart tissue, which is crucial for assessing their potential therapeutic efficacy in cardiovascular diseases.
Innovation Solution
A method involving the use of α-1 acid glycoprotein to coat a matrix, incubation with stem cells labeled with a fluorescent dye, and subsequent fluorescence measurement to quantify binding capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If in vitro assays are used to determine stem cell binding capacity, then the number of animal tests can be reduced and testing speed can be increased, but no existing assay can determine binding capacity to heart tissue
Solution Approach 1:
The patent uses α-1 acid glycoprotein as an intermediary substance that naturally occurs on heart tissue surfaces. This glycoprotein serves as a mediator that allows stem cells to bind to the assay surface in a manner that mimics their natural binding to heart tissue, enabling the in vitro assay to predict in vivo binding capacity without requiring actual heart tissue samples
Solution Approach 2:
The assay creates a simplified copy of the heart tissue binding interface by coating the assay surface with α-1 acid glycoprotein. This copy captures the essential binding characteristics of heart tissue without requiring complex tissue structures, allowing rapid screening of stem cell binding capacity while maintaining physiological relevance
2Reliability
If preclinical tests are performed on animal models, then accurate in vivo behavior can be observed, but the number of animal tests increases and testing time extends
Solution Approach 1:
The patent performs preliminary binding assessment in vitro using α-1 acid glycoprotein-coated surfaces before proceeding to animal studies. This preliminary action screens stem cell candidates for their binding capacity, allowing researchers to select only the most promising candidates for subsequent in vivo testing, thereby reducing the number of animals needed and shortening the overall testing timeline
Solution Approach 2:
The patent segments the testing process into distinct in vitro and in vivo phases, with the in vitro assay using α-1 acid glycoprotein serving as a preparatory filtering step. This segmentation allows the more complex and time-consuming animal studies to be performed on a reduced subset of stem cell candidates, optimizing resource allocation and reducing overall testing duration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the determination of stem cell binding to heart tissue in vitro, predicting their in vivo behavior and potential therapeutic effectiveness.
Implementation Method 1
incubation with stem cells labeled with a fluorescent dye, and subsequent fluorescence measurement to quantify binding capacity
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
A method for determining the binding capacity of stem cells to mammalian heart tissue consists in that: (a) in the well matrix, some of the wells are filled with α-1 acid glycoprotein solution and incubated; (b) after incubation, all wells are filled with a suspension of stem cells labeled with a fluorescent dye and incubated; (c) after incubation, the whole is washed; (d) the fluorescence level is then measured. The object of the invention is also an assay and use of α-1 acid glycoprotein to determine the binding capacity of stem cells.